杭州博拓生物科技股份有限公司2026年第一次临时股东会决议公告

Group 1 - The core point of the announcement is the resolution of the first extraordinary general meeting of shareholders of Hangzhou Botao Biotechnology Co., Ltd. held on January 26, 2026, with no rejected proposals [1][2] - The meeting was convened in accordance with the Company Law, Securities Law, and the company's articles of association, utilizing a combination of on-site and online voting methods [2][5] - The meeting was attended by 6 out of 7 current directors, with one independent director participating via communication, and the company’s vice president and board secretary also present [3] Group 2 - Two main proposals were reviewed: the revision of the company's articles of association and the anticipated daily related party transactions for 2026, both of which were approved [4][5] - The first proposal required a special resolution, passing with more than two-thirds of the voting rights held by attending shareholders, while the second proposal was a general resolution, passing with more than half of the voting rights [5] - The meeting was witnessed by Zhejiang Tian Ce Law Firm, confirming that the convening and proceedings of the meeting complied with legal and regulatory requirements [5]